BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment

  • BriaCell Therapeutics Corp BCTX has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation INCY
  • The Phase 1/2a combination study will evaluate BriaCell's lead candidate, Bria-IMT, with Incyte's retifanlimab & epacadostat to treat advanced breast cancer.
  • BriaCell and Incyte had previously treated two patients under this Phase I/IIa combination study after the corporate collaboration commencement in April 2019
  • Bria-IMT in heavily pretreated advanced breast cancer patients achieved 12 months of average overall survival benefit. The top responder achieved 21.4 months survival plus 100% resolution of an eye-bulging orbital tumor.
  • Price Action: BCTX shares are up 3.25% at $6.04 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsGeneralbreast cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!